Compare FATE & DH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FATE | DH |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 112.1M |
| IPO Year | 2013 | 2021 |
| Metric | FATE | DH |
|---|---|---|
| Price | $2.35 | $1.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $4.10 | $3.08 |
| AVG Volume (30 Days) | ★ 1.1M | 796.5K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.88 | ★ 63.28 |
| EPS | ★ N/A | N/A |
| Revenue | $6,646,000.00 | ★ $241,521,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $0.61 |
| 52 Week High | $3.23 | $4.35 |
| Indicator | FATE | DH |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 65.86 |
| Support Level | $2.27 | $0.93 |
| Resistance Level | $2.55 | $1.10 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 0.00 | 60.35 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.